statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alltrna Announces Updates to Its Board of Directors

Alltrna Announces Updates to Its Board of Directors Alltrna Announces Updates to Its Board of Directors PR Newswire CAMBRIDGE, Mass., July 17, 2024 Chris Schade appointed as Board ChairpersonLynne...

A Closer Look at Cytokinetics's Options Market Dynamics

Peering Into Cytokinetics's Recent Short Interest

Cytokinetics Unusual Options Activity

Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe

Unlock the latest on Royalty Pharma plc & Cytokinetics Inc.'s strategic funding collaboration for aficamten's commercialization and cardiovascular pipeline expansion.

 Latest Ratings for CYTK...

Why Cytokinetics (CYTK) Shares Are Falling

Cytokinetics shares are trading lower by 15.8% during Thursday's session. The company announced the pricing of a public offering of 9,803,922 shares.
read more...

Cytokinetics secures up to $575M in royalty deal, frustrating investors

Cytokinetics secures up to $575M in royalty deal, frustrating investors...

VF Corp Posts Weak Q4 Results, Joins NetEase, Cytokinetics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Cytokinetics presents additional 48-week data from FOREST-HCM study

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73  Annual Scientific Session

Treatment with Aficamten for 48 Weeks is Associated with Improvements in Clinical Efficacy Endpoints, NYHA Class and Cardiac Biomarkers, Structure and FunctionSOUTH SAN FRANCISCO, Calif., April 05...

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Cytokinetics Inc

Volume	1.17M
52-Wk High	$110.25
52-Wk Low	$25.98

CYTK Cytokinetics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals